Home » Stocks » APTO

Aptose Biosciences, Inc. (APTO)

Stock Price: $4.40 USD 0.01 (0.23%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 395.52M
Revenue (ttm) n/a
Net Income (ttm) -48.23M
Shares Out 85.86M
EPS (ttm) -0.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $4.40
Previous Close $4.39
Change ($) 0.01
Change (%) 0.23%
Day's Open 4.39
Day's Range 4.33 - 4.52
Day's Volume 709,033
52-Week Range 4.03 - 9.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 weeks ago

Aptose Biosciences (APTO) has been struggling lately, but the selling pressure may be coming to an end soon.

Seeking Alpha - 1 month ago

Aptose shares are weak in post-ASH trading as the Phase I CG-806 study has yet to produce a clinical response in B-cell malignancies. Three B-cell patients did see some tumor reduction at lowe...

GlobeNewsWire - 1 month ago

SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, Dec...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

Zacks Investment Research - 1 month ago

Aptose (APTO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

GlobeNewsWire - 1 month ago

Corporate event to provide clinical update for CG-806 in AML and B-cell Cancers

The Motley Fool - 2 months ago

Aptose Biosciences and Five Prime Therapeutics both have explosive growth potential.

Other stocks mentioned: FPRX
Seeking Alpha - 2 months ago

Aptose shares have been weak of late, but there have been no negative updates to the company's core clinical programs, and management recently started its third trial (CG-806 in AML). It is un...

Seeking Alpha - 2 months ago

Aptose Biosciences' (APTO) CEO William Rice on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Dosing Initiated in CG-806 Phase 1 a/b Study in AML Patients at 450mg Dose Level

GlobeNewsWire - 2 months ago

Abstracts Accepted for Presentation Abstracts Accepted for Presentation

GlobeNewsWire - 2 months ago

SAN DIEGO and TORONTO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target th...

Zacks Investment Research - 2 months ago

Aptose (APTO) doses first patient with acute myeloid leukemia in a phase I a/b study with CG-806, with a starting dose of 450 mg.

GlobeNewsWire - 2 months ago

Phase 1 a/b Study of CG-806 in AML Initiates with Starting Dose of 450mg Phase 1 a/b Study of CG-806 in AML Initiates with Starting Dose of 450mg

GlobeNewsWire - 4 months ago

SAN DIEGO and TORONTO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target...

GlobeNewsWire - 4 months ago

SAN DIEGO and TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target...

Zacks Investment Research - 4 months ago

Aptose Biosciences (APTO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Seeking Alpha - 4 months ago

APTO's lead candidate, CG-806, is due for important updates in 4Q2020.

GlobeNewsWire - 5 months ago

SAN DIEGO and TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting th...

Seeking Alpha - 5 months ago

Aptose has recently raised more cash, and looks set for its foreseeable clinical trial needs.

Seeking Alpha - 5 months ago

Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

SAN DIEGO and TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target ...

The Motley Fool - 6 months ago

Dilution is on the way.

GlobeNewsWire - 6 months ago

SAN DIEGO and TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced that it has commenced an underwritten pu...

GlobeNewsWire - 6 months ago

Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AML

The Motley Fool - 6 months ago

Can the run for Sarepta Therapeutics, Viela Bio, and Aptose Biosciences continue?

Other stocks mentioned: SRPT, VIE
GlobeNewsWire - 7 months ago

Safety, tolerability and phospho-BTK inhibition at first three CG-806 dose levels in patients with CLL and other B-cell malignancies

GlobeNewsWire - 7 months ago

SAN DIEGO and TORONTO, June 02, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiat...

Seeking Alpha - 8 months ago

Aptose Biosciences' (APTO) CEO William Rice on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

SAN DIEGO and TORONTO, May 05, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiate...

GlobeNewsWire - 8 months ago

Data from patients at first two dose levels; Phase 1a/b study is ongoing Data from patients at first two dose levels; Phase 1a/b study is ongoing

Seeking Alpha - 9 months ago

Aptose Riding Higher As The Street Starts Paying Attention

Seeking Alpha - 10 months ago

Aptose Biosciences Inc. (APTO) CEO William Rice on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

The Motley Fool - 11 months ago

Investing in this emerging cancer-focused biotech may just allow you to retire early.

Zacks Investment Research - 11 months ago

Top Ranked Momentum Stocks to Buy for January 29th

Other stocks mentioned: AGYS, ENPH, VERU
Zacks Investment Research - 1 year ago

Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

GlobeNewsWire - 1 year ago

SAN DIEGO and TORONTO, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced...

The Motley Fool - 1 year ago

Investors excited about the biotech's prospects are taking the opportunity to buy on the dip following the announcement of a new stock offering.

The Motley Fool - 1 year ago

Promising preclinical data and the acquisition of another small biotech continued to generate enthusiasm among investors.

GlobeNewsWire - 1 year ago

SAN DIEGO and TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics t...

GlobeNewsWire - 1 year ago

Aptose Management and KOL’s Discuss Early Clinical Observations with CG-806 and APTO-253 Aptose Management and KOL’s Discuss Early Clinical Observations with CG-806 and APTO-253

GlobeNewsWire - 1 year ago

SAN DIEGO and TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting th...

GlobeNewsWire - 1 year ago

SAN DIEGO and TORONTO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target ...

GlobeNewsWire - 1 year ago

SAN DIEGO and TORONTO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target ...

Seeking Alpha - 1 year ago

Aptose Biosciences, Inc. (APTO) CEO William Rice on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

SAN DIEGO and TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiat...

GlobeNewsWire - 1 year ago

SAN DIEGO and TORONTO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentia...

Seeking Alpha - 1 year ago

Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Aptose Biosciences Inc. (APTO) CEO Dr.

About APTO

Aptose Biosciences, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1b clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase 1a/b clin... [Read more...]

Industry
Biotechnology
Founded
1986
CEO
William Rice
Employees
31
Stock Exchange
NASDAQ
Ticker Symbol
APTO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for APTO stock is "Buy." The 12-month stock price forecast is 4.72, which is an increase of 7.27% from the latest price.

Price Target
$4.72
(7.27% upside)
Analyst Consensus: Buy